Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jeffrey Harper
Harvard Medical School, Department: Anatomy/cell Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rheostat Therapeutics Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The research project seek to mechanistically explore the regulation of various forms of selective autophagy as well as understand how two particular forms of selective autophagy, mitophagy and ferritinophagy, cooperate to regulate critical biological processes. These results have the potential to provide explanations as to the distinct roles of autophagy in different tissues during physiological and pathological states. Dr. Harper is a co-founder of Rheostat Therapeutics. The company is developing treatments for neurodegenerative disease through modulation of mitophagy and autophagy. The company seeks to find small molecules that increase mitophagic flux. The company could therefore have an interest in the research project.
Mechanisms of Selective Autophagy
Selective autophagy involves the recognition and degradation of specific cargo which can play a role in key biological processes such as the regulation of bioavailable iron by ferritinophagy. These studies will elucidate the mechanisms of cargo selectivity of ferritinophagy and other forms of selective autophagy as well as their contributions to critical cellular functions.
Filed on July 31, 2019.
Tell us what you know about Jeffrey Harper's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jeffrey Harper filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jeffrey Harper | Harvard Medical School | Conflict of Interest | Rheostat Therapeutics Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.